Novo Nordisk Denmark - Search News

Novo Nordisk to cap insulin prices in Minnesota settlement

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

MinnPost · 3d

AG Ellison settles with Novo Nordisk to cap out-of-pocket payments for insulin at $35 a month

Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month.

Reuters on MSN · 3d

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

KARE-TV Minneapolis-St. Paul o… · 3d

Novo Norodisk caps insulin prices at $35 for Minnesotans

If you rely on insulin, you will be able to buy Novo Nordisk's products for $35 per month due to a settlement announced Monday.

Pharmabiz2h

Novo Nordisk Foundation granted DKK 10 billion to benefit people and the planet in milestone year

Novo Nordisk Foundation granted DKK 10 billion to benefit people and the planet in milestone year: Denmark Friday, January 31, 2025, 16:00 Hrs [IST] In 2024, on its 100th annivers ...

6don MSN

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Investors Chronicle20h

A pharma stock emerging from Novo Nordisk's shadow

Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance ...

PharmiWeb4d

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

13don MSN

Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk A/S - share repurchase programme

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

Decoding Novo Nordisk's Options Activity: What's the Big Picture?

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

UBS Remains a Buy on Novo Nordisk (0QIU)

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year

In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving ...

A cautionary tale that Europe can’t afford to ignore

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results